🕒 Last update: loading…16/11/2026

Stock CRISPR Therapeutics AG CRSP

CRISPR Therapeutics AG — Investlytic score 3/5 on the five criteria.

-
-
60/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 3/5 criteria met. Data as of 01/11/2026.

  • ✅ Price trend passed
  • ⚠️ Mixed growth
  • ✅ Debt passed
  • ❌ P/E failed
  • ✅ Correction passed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2018 → 2019: 113.18%

Price change 2019 → 2020: 151.39%

Price change 2020 → 2021: -50.51%

Price change 2021 → 2022: -46.36%

Price change 2022 → 2023: 54.00%

Price change 2023 → 2024: -37.12%

Price change 2024 → 2025: 33.23%

Price change 2025 → 2026: -3.83%

Price change 2026 (year to date): -6.21%

Financial growth

Revenue CAGR (8 years): 1.68%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 0.21

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -10.60

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 18.52% from the high over 6 months.

Correction between 10.0% and 20.0% (target range).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
CRISPR Therapeutics AG–0.20–🔒
Option Care Health, Inc.18.40.96+18.7 %–
Merit Medical Systems, Inc.22.30.57+11.5 %–
Legend Biotech Corporation–0.41+60.3 %–
Doximity, Inc.21.20.01+33.4 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by CRISPR Therapeutics AG over the latest fiscal years.

Revenue
3.5 m USD
fiscal year 2025
Net income
-582 m USD
fiscal year 2025
Net margin
-16,569.8 %
fiscal year 2025
Average annual growth
+37.3 %
Revenue growth over 5 years
Average annual growth
+30.4 %
Revenue growth over 10 years
Market cap
4.1 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2020719,000-349 m-48,520.9 %n/a
2021913 m378 m41.4 %+126,893.2 %
2022436,000-650 m-149,122.7 %-100.0 %
2023370 m-154 m-41.5 %+84,762.4 %
202435.0 m-366 m-1,046.4 %-90.5 %
20253.5 m-582 m-16,569.8 %-90.0 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by CRISPR Therapeutics AG over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
1.88
gray zone (1.81 to 2.99)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
-1.28 x
net cash
Fiscal year20212022202320242025
Cash and investments2.4 bn1.8 bn1.7 bn1.9 bn2.0 bn
Total Debt225 m244 m239 m224 m395 m
Net Debt-698 m32.1 m-151 m-74.6 m39.7 m
Equity2.4 bn1.9 bn1.9 bn1.9 bn1.9 bn
Total assets2.8 bn2.2 bn2.2 bn2.2 bn2.3 bn
Operating cash flow539 m-496 m-260 m-143 m-345 m
Investments (capex)81.7 m37.2 m9.5 m1.9 m914,000
Free cash-flow457 m-533 m-270 m-145 m-346 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-8.99 x
Price / book value2.50 x
Return on Equity (ROE)-25.6 %
Return on Invested Capital (ROIC)-21.8 %
Net margin-1,812.1 %
Debt / equity0.47 x
Current ratio16.21 x
Free cash-flow yield-9.2 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

CRISPR Therapeutics AG compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
CRISPR Therapeutics AG4.1 bnn/a-16,569.8 %
Intellia Therapeutics, Inc. NTLA1.4 bnn/a-609.9 %
Beam Therapeutics Inc. BEAM2.4 bnn/a-57.2 %
Editas Medicine, Inc. EDIT335 mn/a-395.0 %
Precision BioSciences, Inc. DTIL211 mn/a-133.4 %
Metagenomi, Inc. Common Stock MGX26.2 mn/a-348.5 %
REGENXBIO Inc. RGNX505 mn/a-113.8 %
Ginkgo Bioworks Holdings, Inc. DNA637 mn/a-183.8 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering CRISPR Therapeutics AG publish: ratings, price targets and earnings forecasts.

Majority rating
buy
38 analysts
Average price target
78.00 USD
from n/a to n/a, 15 targets over 12 months
Gap with the share price
+55.8 %
price 50.07 USD on 06/11/2026

Breakdown of ratings

strong buy 0buy 22hold 14sell 2strong sell 0

Average target over the last 3 months: 78.00 USD (4 targets).

Track record against expectations: reported EPS above consensus 6 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in CRISPR Therapeutics AG.

Free float
99.5 %
share of freely traded shares
Large funds tracked
23
hold the stock as of 2026Q2
Executives (insiders)
0 / 7
0 purchases, 7 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
ARK Investment Management9.5 m516 m3.4 %-16.4 %2026Q2
State Street8.6 m471 m0.0 %+117.0 %2026Q2
BlackRock8.3 m455 m0.0 %+8.7 %2026Q2
Capital World Investors4.7 m259 m0.0 %+0.5 %2026Q2
Geode Capital Management2.5 m137 m0.0 %+5.6 %2026Q2
Vanguard Group2.3 m119 m0.0 %-4.1 %2025Q4
Two Sigma Investments2.0 m108 m0.1 %+34.1 %2026Q2
Fidelity1.9 m104 m0.0 %-2.4 %2026Q2

Latest insider transactions

DatePersonSideAmount
19/10/2026Kulkarni Samarthsale2.4 m USD
14/10/2026George Simeonsale720,373 USD
14/10/2026Kasinger James R.sale51,230 USD
14/10/2026Kulkarni Samarthsale201,867 USD
06/10/2026Kasinger James R.sale119,481 USD
22/09/2026Kasinger James R.sale626,460 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 16/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 19/10/2016
ISIN code
CH0334081137
Workforce
393
full-time employees
Chief executive
Samarth Kulkarni

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about CRISPR Therapeutics AG

What is the CRISPR Therapeutics AG share price?

Latest recorded price: 42.24 USD on 13/11/2026, for a market cap of 4.1 bn USD.

What is the revenue of CRISPR Therapeutics AG?

3.5 m USD for fiscal year 2025, with net income of -582 m USD (net margin -16,569.8 %).

What do analysts say about CRISPR Therapeutics AG?

Out of 38 analysts: 22 buy or strong buy, 14 hold, 2 sell or strong sell. Average price target: 78.00 USD, i.e. +55.8 % from the share price.

Is CRISPR Therapeutics AG stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN CH0334081137).

How many employees does CRISPR Therapeutics AG have?

393 full-time employees according to the latest published profile.

Who runs CRISPR Therapeutics AG?

Samarth Kulkarni is the company's chief executive.

Which large funds own CRISPR Therapeutics AG?

As of 2026Q2, among the large funds tracked: ARK Investment Management, State Street, BlackRock, Capital World Investors, Geode Capital Management.

07

Similar stocks